Zealand Pharma As Stock Today
| ZLDPF Stock | USD 104.20 1.45 1.41% |
Performance0 of 100
| Odds Of DistressLess than 36
|
Zealand Pharma is trading at 104.20 as of the 25th of November 2024. This is a 1.41 percent up since the beginning of the trading day. The stock's lowest day price was 104.2. Zealand Pharma has about a 36 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Zealand Pharma AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Zealand Pharma AS, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 51.28 M outstanding shares. More on Zealand Pharma AS
Moving together with Zealand Pink Sheet
| 0.79 | NVO | Novo Nordisk AS | PairCorr |
| 0.77 | NONOF | Novo Nordisk AS | PairCorr |
| 0.71 | CSLLY | CSL | PairCorr |
| 0.74 | REGN | Regeneron Pharmaceuticals | PairCorr |
Moving against Zealand Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Zealand Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Zealand Pharma AS [ZLDPF] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.57 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zealand Pharma's market, we take the total number of its shares issued and multiply it by Zealand Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Zealand Pharma AS classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 51.28 M outstanding shares.
Zealand Pharma AS has accumulated about 864.44 M in cash with (1.21 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.68.
Check Zealand Pharma Probability Of Bankruptcy
Ownership AllocationZealand Pharma AS retains a total of 51.28 Million outstanding shares. Over half of Zealand Pharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Zealand Ownership Details
Zealand Pharma AS Risk Profiles
| Mean Deviation | 2.24 | |||
| Standard Deviation | 3.03 | |||
| Variance | 9.16 | |||
| Risk Adjusted Performance | (0.07) |
Zealand Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Zealand Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Zealand Pharma Corporate Management
| Henriette Wennicke | Chief Officer | Profile | |
| Lani Morvan | Investor Officer | Profile | |
| Adam MD | Pres CEO | Profile | |
| Mads Kronborg | Head Communication | Profile | |
| Ravinder Chahil | Sr Counsel | Profile | |
| Danilo Verge | Head Affairs | Profile |
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.